Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What’s Next for Dynavax Technologies Corporation (DVAX)?

Dynavax Technologies Corporation (NASDAQ:DVAX) is down more than 30% in early trading today following a Food and Drug Administration rejection for its hepatitis B vaccine Heplisav. The FDA cited safety and manufacturing concerns but indicated a willingness to consider a more limited approval. What’s next for Dynavax’s lead drug candidate?

Rejection recalibration
Hepatitis B is an infectious disease that affects the liver. Acute patients may show few symptoms, but chronic cases can lead to cirrhosis and other potentially fatal conditions.

Dynavax Technologies Corporation (NASDAQ:DVAX)Heplisav was closely watched last year because it presented similar efficacy as GlaxoSmithKline plc (ADR) (NYSE:GSK)‘s Engerix-B, but offered vast dosage improvement. Glaxo’s drug includes up to four doses given over the span of six months; Dynavax’s drug has two doses given in one month. The approval of Heplisav may significantly increase the lackluster rates of vaccine adherence.

But that time hasn’t come… yet.

Heplisav’s complete response letter from the FDA wasn’t shocking. An advisory panel last fall voted against the drug’s safety but in favor of efficacy. The panel’s main problems were the lack of diversity in trial participants and the fact that the drug includes a novel adjuvant. Vaccines often include adjuvants, which improve the chances of an immune response, but the panel noted that Heplisav’s might pose severe autoimmune risks.

The FDA’s willingness to talk about a restricted approval indicates that Heplisav still has a shot at getting to market for at-risk patients, such as older patients with diabetes since the risks of hepatitis B could outweigh the possible side effects of the drug. A narrow approval would beat no approval, but Dynavax will need to seek broader indications further down the line.

What now?
Heplisav remains under review in the EU for the general adult population and those with chronic kidney disease — a common comorbidity for hepatitis B.

Dynavax should meet with the FDA within the next six weeks to discuss Heplisav’s future. If the company wants approval, it will take the narrower treatment population. But Dynavax should simultaneously circle back for further trials that include a more diverse population and better safety data.

The article What’s Next for Dynavax? originally appeared on and is written by Brandy Betz.

Fool contributor Brandy Betz owns no shares of the companies mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!